TScan Therapeutics, Inc.
TCRX
$0.97
$0.1315.33%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 5.46% | -1.78% | -28.12% | -30.99% | -35.83% |
| Total Depreciation and Amortization | -18.43% | -30.23% | -38.98% | -36.91% | -30.96% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 25.71% | 29.86% | 72.78% | 42.53% | 52.64% |
| Change in Net Operating Assets | -1,471.63% | -459.68% | 82.85% | -104.57% | -95.98% |
| Cash from Operations | -2.41% | -22.10% | -21.98% | -77.12% | -77.72% |
| Capital Expenditure | 36.69% | -15.22% | -50.44% | -46.71% | -54.40% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 239.84% | 333.21% | 270.22% | 122.34% | -240.29% |
| Cash from Investing | 227.28% | 307.88% | 256.21% | 112.11% | -216.72% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.24% | -99.25% | -98.37% | -94.64% | -19.83% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.05% | -100.38% | -77.08% | -77.07% | 70.87% |
| Cash from Financing | -99.91% | -100.16% | -72.24% | -71.22% | 53.26% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -291.62% | -157.98% | 264.84% | -318.40% | -69.72% |